Emerging prognostic factors in Nasopharyngeal carcinoma.

N. A Iacovelli, P Bossi, C Fallai, G Gardani, Ester Orlandi

Abstract


Identification and validation of prognostic factors in NPC has been mainly performed in areas where the disease is endemic. It is matter of debate if the same variables will retain their impact when applied to non-endemic areas, with prevalence of other histological subtypes and with a different genetic background.

Keywords


Nasopharyngeal Carcinoma; Prognostic Factors

Full Text:

HTML PDF Citation

References


Langendijk JA, Leemans CR, Buter J, et al: The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. J ClinOncol 22:4604-4612, 2004.

Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099. J Clin Oncol 16:1310-1317, 1998.

Lee AW, Tung SY, Chan AT, et al: Preliminary results of a randomized study (NPC-9902 Trial) on therapeutic gain by concurrent chemotherapy and/or accelerated fractionation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 66:142-151, 2006.

Lee AW, Lau WH, Tung SY, et al: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 23:6966-6975, 2005.

Wee J, Tan EH, Tai BC, et al: Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol23:6730-6738, 2005.

Lee AW, Sze WM, Au JS, et al: Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys 61:1107-1116, 2005.

OuYang PY, Xie C, Mao YP, Zhang Y, Liang XX, Su Z, Liu Q, Xie FY; Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol. 2013 Aug;24(8):2136-46. doi: 10.1093/annonc/mdt146. Epub 2013 Apr 23.

Greene FL, Page DL et al (2002) AJCC cancer staging handbook from the AJCC cancer staging manual, 6th edn. Springer, New York, pp 47–60.

Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz AG, Greene FL, Trotti A: AJCC Cancer Staging Manual. 7th edition. Philadelphia: Lippincott-Raven; 2009.

Qi Shi, Chunying Shen, Lin Kong, Xiaoshen Wang, Jianhui Ding, Yunsheng Gao, Tingting Xu and Chaosu Hu; Involvement of both Cervical Lymph Nodes and Retropharyngeal Lymph Nodes has prognostic value for N1 patients with Nasopharyngeal Carcinoma. Radiation Oncology 2014, 9:7.

Lin S, Pan J, Han L et al (2009) Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series. Int J Radiat Oncol Biol Phys 75:1071–1078.

Tham IW, Hee SW, Yeo RM et al (2009) Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the National Cancer Centre Singapore experience. Int J Radiat Oncol Biol Phys 75:1481–1486.

D Liu, G Long, Q Mei, G Hu.; Primary tumor volume should be included in the TNM staging system of nasopharyngeal carcinoma. Medical Hypotheses 82 (2014) 486–487

Gallo O, Bianchi S, Giannini A, Gallina E, Libonati GA, Fini-Storchi O; Correlations between histopathological and biological findings in nasopharyngeal carcinoma and its prognostic significance. Laryngoscope. 1991 May;101(5):487-93.

Kaasa S, Kragh-Jensen E, Bjordal K, Lund E, Evensen JF, Vermund H, Monge O, Boehler P; Prognostic factors in patients with nasopharyngeal carcinoma. Acta Oncol. 1993;32(5):531-6.

H. Chang, J. Gao, B.Q. Xu, S.P. Guo, R.B. Lu, G. Li, S.M. Huang, F. Han, Z.G. Liu, Y.L. Tao, Z.W. Tu, C. Chen, X.H. Li, Y.F. Xia; Haemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction of the TNM Staging System in Nasopharyngeal Carcinoma: Development and Validation in 3237 Patients from a Single Institution. Clinical Oncology 25 (2013) 639e646.

Liu L, Liang S, Li L, Mao Y, Tang L, Tian L, Liao X, Cui C, Lin A, Ma J (2009) Prognostic impact of magnetic resonance imaging-detected cranial nerve involvement in nasopharyngeal carcinoma. Cancer 115: 1995–2003.

X Liu, L-Z Liu, Y-P Mao, L Chen, L-L Tang, G-Q Zhou, Y Sun, D Yue, A-H Lin, L Li and J Ma, Prognostic value of magnetic resonance imaging-detected cranial nerve invasion in nasopharyngeal carcinoma. British Journal of Cancer (2014) 110, 1465–1471 | doi: 10.1038/bjc.2014.27.

Teo PM, Leung SF, Tung SY et al. Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG). Radiother. Oncol. (2006) 79, 27–33.

Kwong DL, Sham JS, Chua DT, Choy DT, Au GK, Wu PM. The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. (1997) 39, 703–710.

Dubben HH, Thames HD, Beck-Bornholdt HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol 1998;47:167–74.

Guo R, Sun Y, Yu XL, Yin WJ, Li WF, Chen YY, et al. Is primary tumor volume still a prognostic factor in intensity modulated radiation therapy for nasopharyngeal carcinoma? Radiother Oncol 2012;104:294–9.

Mei Feng, Weidong Wang, Zixuan Fan, Binyu Fu, Jie Li, Shichuan Zhang and Jinyi Lang; Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Radiation Oncology 2013, 8:208.

Zheng Wu, Yong Su, Rui‑Fang Zeng, Mo‑Fa Gu, Shao‑Min Huang; Prognostic value of tumor volume for patients with nasopharyngeal carcinoma treated with concurrent chemotherapy and intensity‑modulated radiotherapy. J Cancer Res Clin Oncol (2014) 140:69–76.

Chen C, Fei Z, Pan J, Bai P, Chen L. Significance of primary tumor volume and T stage on prognosis in nasopharyngeal carcinoma treated with intensity modulated radiation therapy. Jpn J Clin Oncol 2011;41:537–42.

Shao-Bo Liang, Yan-Ming Deng, Ning Zhang, Rui-Liang Lu, Hai Zhao, Hai-Yang Chen, Shao-En Li, Dong-Sheng Liu and Yong Chen; Prognostic significance of maximum primary tumor diameter in nasopharyngeal carcinoma. BMC Cancer 2013, 13:260.

Dongbo Liu, Guoxian Long, Qi Mei, Guoqing Hu; Primary tumor volume should be included in the TNM staging system of nasopharyngeal carcinoma. Medical Hypotheses 82 (2014) 486–487.

Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 2012;104:286–93.

Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for earlystage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66:981–91.

Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensitymodulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007;25:4873–9.

Fang FM, Chien CY, Tsai WL, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy-a longitudinal study. Int J Radiat Oncol Biol Phys 2008;72:356–64.

Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, Chan OS, Chang AT, Yeung RM; Evolution of treatment for nasopharyngeal cancer - Success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014 Mar 11. S0167-8140(14)00043-7. doi: 10.1016/j.radonc.2014.02.003.

Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59: 1188-1191.

Ma BB et al. Relationship between pretreatment level of plasma Epstein–Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:714–20.

Lo YM et al. Plasma cell-free Epstein–Barr virus DNA quantitation in patients with nasopharyngeal carcinoma. Correlation with clinical staging. Ann NY Acad Sci 2000;906:99–101.

Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004; 350: 2461-2470.

Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003; 98: 288-291.

Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, Mo F, Lai M, Ho S, Huang DP, Johnson PJ. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst. 2002 Nov 6;94(21):1614-9.

Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350(24):2461-70.

Le QT, Jones CD, Yau TK, et al. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res 2005;11(16):5700-7.

Timothy T.C. Yip, Roger K.C. Ngan, Alvin H.W. Fong, Stephen C.K. Law; Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma; Oral Oncology 2014 in press.

Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004.

Chan AT, Ma BB, Lo YM, Leung SF, Kwan WH, Hui EP, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol 2004; 22: 3053-3060.

Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614-1619.

Lin JC, Wang WY, Liang WM, Chou HY, Jan JS, Jiang RS, et al. Long-term prognostic effects of plasma Epstein–Barr virus DNA by minor groove binderprobe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;68(5):1342–8.

Liang FY, Sun W, Han P, Lu X, Lian YN, Huang XM. Detecting plasma Epstein–Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study. Chin J Cancer 2012;31(3):142–9.

Leung SF, Lo YM, Chan AT, To KF, To E, Chan LY, et al. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein–Barr virus DNA. Clin Cancer Res 2003;9(9):3431–4.

Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W, Voravud N, Mutirangura A. Epstein–Barr virus DNA in serum/plasma as a tumor marker for nasopharyngeal cancer. Clin Cancer Res 2000;6(3):1046–51.

Zhang Y, Gao HY, Feng HX, Deng L, Huang MY, Hu B, et al. Quantitative analysis of Epstein–Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal carcinoma. Zhonghua Yi Xue Za Zhi 2004;84(12):982–6.

Wang WY, Twu CW, Lin WY, Jiang RS, Liang KL, Chen KW, et al. Plasma Epstein–Barr virus DNA screening followed by 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting post treatment failures of nasopharyngeal carcinoma. Cancer 2011;117(19):4452–9.

Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004 Jun 10;350(24):2461–70.

Hong RL, Lin CY, Ting LL, Ko JY, Hsu MM. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein–Barr virus DNA. Cancer 2004;100(7):1429–37.

Kalpoe JS, Dekker PB, van Krieken JH, Baatenburg de Jong RJ, Kroes AC. Role of Epstein–Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinomain a low risk area. J Clin Pathol 2006;59(5):537–41.

Shi W, Pataki I, MacMillan C, Pintilie M, Payne D, O’Sullivan B, et al. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002; 94: 1997-2006.

Ke Kengjian, Wang Haiyun, Fu Sha, Zhang Zichen, Duan Liping, Liu Dabo and Ye Jin; Epstein-Barr virus-encoded RNAs as a survival predictor in nasopharyngeal carcinoma. Chin Med J 2014;127.

Lo EJ, Bell D, Woo JS, et al. Human papillomavirus and WHO type I nasopharyngeal carcinoma. Laryngoscope 2010;120:1990-1997.

Maxwell JH, Kumar B, Feng FY, et al. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans.Head Neck 2010;32:562-567.

Punwaney R, Brandwein MS, Zhang DY, et al. Human papillomavirus may be common within nasopharyngeal carcinoma of Caucasian Americans: Investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction. Head Neck 1999;21:21-29.

Tung YC, Lin KH, Chu PY, et al. Detection of human papilloma virus and Epstein-Barr virus DNA in nasopharyngeal carcinoma

by polymerase chain reaction. Kaohsiung J Med Sci 1999;15:256-262.

Giannoudis A, Ergazaki M, Segas J, et al. Detection of Epstein-Barr virus and human papillomavirus in nasopharyngeal carcinoma by the polymerase chain reaction technique. Cancer Lett 1995;89:177-181.

Hording U, Nielsen HW, Daugaard S, et al. Human papillomavirus types 11 and 16 detected in nasopharyngeal carcinomas by the polymerase chain reaction. Laryngoscope 1994;104:99-102.

Lin Z, Khong B, Kwok S, et al. Human papillomavirus 16 detected in nasopharyngeal carcinomas in Caucasian Americans but not in endemic southern Chinese patients. Head Neck 2013 Apr 25 [Epubahead of print]. doi: 10.1002/hed.23362.

Dogan S, Hedberg ML, Ferris RL, et al. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck 2013 Jun 18 [Epub ahead of print]. doi: 10.1002/hed.23318.

Robinson M, Suh YE, Paleri V, et al. Oncogenic human papillomavirus associated nasopharyngeal carcinoma: An observational study of correlation with ethnicity, histological subtype and outcome in a UK population. Infect Agent Cancer 2013;8:30.

Laantri N, Attaleb M, Kandil M, et al. Human papillomavirus detection in moroccan patients with nasopharyngeal carcinoma. Infect Agent Cancer 2011;6:3.

Mirzamani N, Salehian P, Farhadi M, et al. Detection of EBVand HPV in nasopharyngeal carcinoma by in situ hybridization. Exp Mol Pathol 2006;81:231-234.

Rassekh CH, Rady PL, Arany I, et al. Combined Epstein-Barr virus and human papillomavirus infection in nasopharyngeal carcinoma. Laryngoscope 1998;108:362-367.

Tyan YS, Liu ST, Ong WR, et al. Detection of Epstein-Barr virus and human papillomavirus in head and neck tumors. J Clin Microbiol 1993;31:53-56.

Matthew H. Stenmark, Jonathan B. McHugh, Matthew Schipper, Heather M. Walline, Christine Komarck, Felix Y. Feng, Francis P. Worden, Gregory T. Wolf, Douglas B. Chepeha, Mark E. Prince, Carol R. Bradford, Suresh K. Mukherji, Avraham Eisbruch, and Thomas E. Carey; Nonendemic HPV-Positive Nasopharyngeal Carcinoma: Association With Poor Prognosis. Int J Radiation Oncol Biol Phys, Vol. 88, No. 3, pp. 580e588, 2014.

Yen-Kung Chen, Ru-Hwa Cheng Kwan-Hwa Chi, Jia-Guang Liang, Su-Chen Wang,Yeh-You Shen, Alfred C. Liao, Chen-Tau Su. Application of 18F-FDG PET/CT in Nasopharyngeal Carcinoma Ann Nucl Med Sci 2007;20:21-32.

Lee SW, Nam SY, Im KC, Kim JS, Choi EK, Ahn SD, et al. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008;87:211–6.

Xie P, Yue JB, Fu Z, Feng R, Yu JM. Prognostic value of 18F-FDG PET/CT before and after radiotherapy for locally advanced nasopharyngeal carcinoma. Ann Oncol 2010;21:1078–82.

Chan SC, Chang JT, Lin CY, Ng SH, Wang HM, Liao CT, Chang CJ, Lin SY, Yen TC. Clinical utility of 18F-FDG PET parameters in patients with advanced nasopharyngeal carcinoma: predictive role for different survival endpoints and impact on prognostic stratification.

Wen-Shan Liu, Ming-Fang Wu, Hsien-Chun Tseng, Jung-Tung Liu, Jui-Hung Weng, Yueh-Chun Li, and Jong-Kang Lee; The role of pretreatment FDG-PET in nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. Int. J. Radiation Oncology Biol. Phys., Vol. 82, No. 2, pp. 561–566, 2012.

Winnie K. S. Chan, Dora Lai-Wan Kwong, David W. C. Yeung, Bingsheng Huang, and Pek-Lan Khong; Prognostic Impact of Standardized Uptake Value of F-18 FDG PET/CT in Nasopharyngeal Carcinoma. Clin Nucl Med 2011;36: 1007–1011.

Tsung-Min Hung, Hung-Ming Wang, Chung-Jan Kang, Shiang-Fu Huang, Chun-Ta Liao, Sheng-Chieh Chan, Shu-Hang Ng, I-How Chen, Chien-Yu Lin, Kang-Hsing Fan,Joseph Tung-Chieh Chang; Pretreatment 18F-FDG PET standardized uptake value of primary tumor and neck lymph nodes as a predictor of distant metastasis for patients with nasopharyngeal carcinoma. Oral Oncology 49 (2013) 169–174.

Peng Xie, Jin-Bo Yue, Han-xi Zhao, Xin-Dong Sun, Li Kong, Zheng Fu, Jin-Ming Yu; Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol (2010) 136:883–889.

Chan SC, Ng SH, Chang JT, Lin CY, Chen YC, Chang YC, et al. Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2006;33:1032–40.

Chan SC, Yen TC, Ng SH, Lin CY, Wang HM, Liao CT, et al. Differential roles of 18F-FDG PET in patients with locoregional advanced nasopharyngeal carcinoma after primary curative therapy: response evaluation and impact on management. J Nucl Med. 2006;47:1447–54.

Prognostic implications of post-therapy 18F-FDG PET in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy.

Razek A, Kamal E; Nasopharyngeal carcinoma: correlation of apparent diffusion coefficient value with prognostic parameters. Radiol med (2013) 118:534–539.

DeVries AF, Kremser C, Hein PA, et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:958-965.

Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high B-value diffusion-weighted magnetic resonance imaging. J Clin Oncol. 2003;21:1094-1100.

Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 2006;241:839-846.

Vandecaveye V, Dirix P, De Keyzer F, et al. Predictive value of diffusion-weighted magnetic resonance imaging during chemoradiotherapy for head and neck squamous cell carcinoma. Eur Radiol. 2010;20:1703-1714.

Hatakenaka M, Nakamura K, Yabuuchi H, et al. Pretreatment apparent diffusion coefficient of the primary lesion correlates with local failure in head-and-neck cancer treated with chemoradiotherapy or radiotherapy. Int J Radiat Oncol Biol Phys. 2011;81:339-345.

Chung C, Jalali S, Foltz W, et al. Imaging biomarker dynamics in an intracranial murine glioma study of radiation and antiangiogenic therapy. Int J Radiat Oncol Biol Phys. 2013;85:805-812.

Jinsheng Hong, Yiqi Yao; Value of Magnetic Resonance Diffusion-Weighted Imaging for the prediction of radiosensitivity in nasopharyngeal carcinoma. Otolaryngology–Head and Neck Surgery 149(5) 707–713.

Xia W-X, Ye Y-F, Lu X, Wang L, Ke L-R, et al. (2013) The Impact of Baseline Serum C-Reactive Protein and C-Reactive Protein Kinetics on the Prognosis of Metastatic Nasopharyngeal Carcinoma Patients Treated with Palliative Chemotherapy. PLoS ONE 8(10): e76958. doi:10.1371/journal.pone.0076958.

Turen S, Ozyar E, Altundag K, Gullu I, Atahan IL. Serum lactate dehydrogenase level is a prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy. Cancer Invest 2007;25(5):315–21.

Li G, Gao J, Tao YL, et al. Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma. Chin J Cancer 2012;31(4):197–206.

Xiang-bo Wana, Li Wei, Hao Li, Min Dong, Qu Lin, Xiao-kun Maa, Pei-yu Huang, Jing-yun Wen, Xing Li, Jie Chen, Dan-yun Ruan, Ze-xiao Lin, Zhan-hong Chen, Quentin Liu, Xiang-yuan Wua, Ming-huang Hong; High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma. European Journal of Cancer (2013) 49, 2356– 2364.

Wan XB, Fan XJ, Chen MY, et al. Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy 2010;6(3):395–404.

Acikalin MF, Etiz D, Gurbuz MK, Ozudogru E, Canaz F, Colak E. Prognostic significance of galectin-3 and cyclin D1 expression in undifferentiated nasopharyngeal carcinoma. Med Oncol 2012;29(2):742–9.

Zhengbo Wei, Xianjie Zeng, Jian Xu, Xuwei Duan, Jianbo Yang, Ying Xie, PhD; Prognostic value of the pretreatment serum level of cytokeratin fraction 21-1 in undifferentiated nasopharyngeal carcinoma: A study of 332 cases. HEAD & NECK—DOI 10.1002/HED JANUARY 2014.

Li-na Liu, Pei-yu Huang, Zhi-rui Lin, Li-juan Hu, Jian-zhong Liang, Man-zhi Li, Lin-quan Tang, Mu-sheng Zeng, Qian Zhong and Bo-hang Zeng; Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis. Journal of Translational Medicine 2013, 11:140.

Tae-Jung Kim, Youn Soo Lee, Jin-Hyung Kang, Yeon-Sil Kim, and Chang Suk Kang; Prognostic significance of expression of VEGF and Cox-2 in Nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR. Journal of Surgical Oncology 2011;103:46–52.

Liu Z, Yang H, Luo W, Jiang Q, Mai C, Chen Y, Zhen Y, Yu X, Long X, Fang W. Loss of cytoplasmic KLF4 expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma. Histopathology. 2013 Sep;63(3):362-70. doi: 10.1111/his.12176. Epub 2013 Jun 12.

Jiang Q, Mai C, Yang H, Wu Q, Hua S, Yan C, Long Y, Zhang Y, Long X, Fang W, Liu Z. Nuclear expression of CDK4 correlates with disease progression and poor prognosis in human nasopharyngeal carcinoma. Histopathology. 2014 Apr;64(5):722-30. doi: 10.1111/his.12319. Epub 2013 Dec 31.

Lee SW, Lin CY, Tian YF, Sun DP, Lin LC, Chen LT, Hsing CH, Huang CT, Hsu HP, Huang HY, Wu LC, Li CF, Shiue YL Overexpression of CDC28 protein kinase regulatory subunit 1B confers an independent prognostic factor in nasopharyngeal carcinoma. APMIS. 2014 Mar;122(3):206-14. doi: 10.1111/apm.12136. Epub 2013 Jul 24.

Jie Yanga, Lei Lia, Yanxin Rena, Xiaojiang Li, Yanling Tu, Jing Ma, Ruimei Sun, Liufang Zhao, Clinical Significance of Joint Detection of CD44v6 and CD62P in Nasopharyngeal Carcinoma. Onkologie 2013;36:629–634.

SHI-SHENG LI, JIA-JIA LIU, SHUANG WANG, QING-LAI TANG, BING-BING LIU and XIN-MING YANG; Clinical significance of TrkB expression in nasopharyngeal carcinoma. ONCOLOGY REPORTS 31: 665-672, 2014.

Li-Jung Ma, Sung-Wei Lee, Li-Ching Lin, Tzu-Ju Chen, I-Wei Chang, Han-Ping Hsu, Kwang-Yu Chang, Hsuan-Ying Huang, Chien-Feng Li; Fibronectin overexpression is associated with latent membrane protein 1 expression and has independent prognostic value for nasopharyngeal carcinoma. Tumor Biol. (2014) 35:1703–1712.

Daye Cheng, Hong Kong, Yunhui Li; Prognostic value of interleukin-8 and MMP-9 in nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol (2014) 271:503–509.

Yu Xu, Peizhong Li, Xin Zhang, Junying Wang, Dongsheng Gu and Yao Wang; Prognostic implication of neuropilin-1 upregulation in human nasopharyngeal carcinoma. Diagnostic Pathology 2013, 8:155.

Jian Wang, Jing Yang, Bin-Bin Li, Zhi-Wei He; High Cytoplasmic Expression of the Orphan Nuclear Receptor NR4A2 Predicts Poor Survival in Nasopharyngeal Carcinoma. Asian Pacific J Cancer Prev, 14 (5), 2805-2809.

Jui Lan, Hsuan-Ying Huang, Sung-Wei Lee, Tzu-Ju Chen, Hui-Chun Tai, Han-Ping Hsu, Kwang-Yu Chang, Chien-Feng Li; TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma. Tumor Biol. (2014) 35:179–187.

Han-Ping Hsu, Chien-Feng Li, Sung-Wei Lee, Wen-Ren Wu, Tzu-Ju Chen, Kwang-Yu Chang, Shih-Shin Liang, Chia-Jung Tsai, Yow-Ling Shiue; Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma. Tumor Biol. (2014) 35:2619–2629.

Hao-Yuan Mo, Dong-Hua Luo, Hui-Zhi Qiu, Huai Liu, Qiu-Yan Chen, Lin-Quan Tang, Zong-Liang Zhong, Pei-Yu Huang, Zheng-Jun Zhao, Chang-Qing Zhang, Ying Zhang, Hai-Qiang Mai; Elevated Serum Endostatin Levels are Associated with Poor Survival in Patients with Advanced-stage Nasopharyngeal Carcinoma. Clinical Oncology 25 (2013) 308e317.

Si-Wei Li, MD, Hua Wang, MD, Yan-Qun Xiang, Hai-Bo Zhang, Xing Lv, Wei-Xiong Xia; Mu-Sheng Zeng, Hai-Qiang Mai, Ming-Huang Hong, Xiang Guo; Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epstein–Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma. HEAD & NECK—DOI 10.1002/HED APRIL 2013.

Jia-Xing Zhang, Man-Bo Cai, Xiao-Pai Wang, Li-Ping Duan, Qiong Shao, Zhu-Ting Tong, Ding-Zhun Liao, Yang-Yang Li, Ma-Yan Huang, Yi-Xin Zeng, Jian-Yong Shao; Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma. Med Oncol (2013) 30:390.

Jianbo Zhou, Xuping Xiao, Hongmei Yi, Jihua Wang, Xiaoan Wang, Qiuhang Zhang; Upregulation of Gp96 Correlates with the Radiosensitivity and Five-Year Survival Rate of Nasopharyngeal Carcinoma. ORL 2012;74:164–171.

Zheng J, Li J, Xu L, Xie G, Wen Q, et al. (2014) Phosphorylated Mnk1 and eIF4E Are Associated with Lymph Node Metastasis and Poor Prognosis of Nasopharyngeal Carcinoma. PLoS ONE 9(2): e89220. doi:10.1371/journal.pone.0089220.

Yan Fei Deng, Dong Ni Zhou, Chun Sheng Ye, Liang Zeng, Ping Yin; Aberrant Expression Levels of MTAl and RECK in Nasopharyngeal Carcinoma: Association With Metastasis, Recurrence, and Prognosis. Annals of Otology, Rhinology & Laryngology 121(7):457-465.

Christos K Kontos, Ali Fendri, Abdelmajid Khabir, Raja Mokdad-Gargouri and Andreas Scorilas; Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: a retrospective cohort study. BMC Cancer 2013, 13:293.

Zhen Liu, Yufei Long, Yajie Zhang, Wei Huang, Xiaobin Long, Huiling Yang,Jie Long, Chao Cheng, andWeiyi Fang; Nuclear p27 Expression Confers a Favorable Outcome for Nasopharyngeal Carcinoma Patients. Disease Markers Volume 35 (2013), Issue 6, Pages 925–932.

Qingping Jiang, Huiling Yang, Chao Cheng, Hanzhen Xiong, Shaoyan Liu, Jie Long, Yajie Zhang, Weiyi Fang and Zhen Liu; Decreased P27 protein expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma. Jiang et al. Diagnostic Pathology 2013, 8:212.

Wei Sun, Guoxian Long, Junfeng Wang, Qi Mei, Dongbo Liu, Guoqing Hu; Prognostic role of epidermal growth factor receptor in nasopharyngeal carcinoma: A meta-analysis. HEAD & NECK—DOI 10.1002/HED MONTH 2013.

Gong L, Zhang W, Zhou J, Lu J, Xiong H, et al. (2013) Prognostic Value of HIFs Expression in Head and Neck Cancer: A Systematic Review. PLoS ONE 8(9): e75094. doi:10.1371/journal.pone.0075094.

Wang HY, Sun BY, Zhu ZH, Chang ET, To KF, Hwang JS, Jiang H, Kam MK, Chen G, Cheah SL, Lee M, Liu ZW, Chen J, Zhang JX, Zhang HZ, He JH, Chen FL, Zhu XD, Huang MY, Liao DZ, Fu J, Shao Q, Cai MB, Du ZM, Yan LX, Hu CF, Ng HK, Wee JT, Qian CN, Liu Q, Ernberg I, Ye W, Adami HO, Chan AT, Zeng YX, Shao JY; Eight-signature classifier for prediction of nasopharyngeal [corrected] carcinoma survival. J Clin Oncol. 2011 Dec 1;29(34):4516-25. doi: 10.1200/JCO.2010.33.7741. Epub 2011 Oct 24.

Na Liu, Rui-Xue Cui, Ying Sun, Rui Guo, Yan-Ping Mao, Ling-Long Tang, Wei Jiang, Xu Liu, Yi-Kan Cheng, Qing-Mei He, William C.S. Cho, Li-Zhi Liu, Li Li and Jun Ma; A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int. J. Cancer (2014): 134, 1359–1368.

Fang FM, Tsai WL, Chien CY, Chen HC, Hsu HC, Huang TL, Lee TF, Huang HY, Lee CH; Pretreatment quality of life as a predictor of distant metastasis and survival for patients with nasopharyngeal carcinoma. J Clin Oncol. 2010 Oct 1;28(28):4384-9. doi: 10.1200/JCO.2010.28.8324. Epub 2010 Aug 16.

Jin Y, Cai XY, Cai YC, et al. To build a prognostic score model containing indispensable tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area. Eur J Cancer 2012;48(6):882-8.

Ong YK, Heng DM, Chung B, et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer 2003;39(11):1535-41.

Toh CK, Heng D, Ong YK, Leong SS, Wee J, Tan EH. Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer 2005;92(8):1382-7.

Chuangzhen Chen, Siqia Chen, Quynh-Thu Le Jianzhou Chen, Zhijian Chen, Dongsheng Li, Mingzhen Zhou,Derui Li; Prognostic model for distant metastasis in locally advanced nasopharyngeal carcinoma after concurrent chemoradiotherapy. HEAD & NECK—DOI 10.1002/HED MONTH 2014.

Y-M Tian, Y-H Tian, L Zeng, S Liu, Y Guan, T-X Lu and F Han; Prognostic model for survival of local recurrent nasopharyngeal carcinoma with intensity-modulated radiotherapy. British Journal of Cancer (2014) 110, 297–303 | doi: 10.1038/bjc.2013.715.

Xiao-Lin Luo, Wang He, Hui Huang, Qiu-Yan Chen, Ying Liang, Hai-Qiang Mai, Hui-Qiang Huang, Qing-Qing Cai; Design of a Prognostic Score Model for Nasopharyngeal Carcinoma. Head Neck. 2014 Mar 6. doi: 10.1002/hed.23642.




DOI: http://dx.doi.org/10.15383/jnpc.8

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

eISSN: 2312-0398

Asia Press is a professional Science, Technology and Medicine publisher, who owns rapid publication, Peer-Reviewed, Open Access Journals. Asia Press aims to promote “knowledge sharing”. As you know, the main barrier for free “knowledge sharing” is the cost of publishing and transfer. In order to encourage scholars and scientists to the max, and devote whole power to realize the aim of “knowledge sharing” and the benefit of “all” mankind, Asia Press performs a permanent policy of no charge for publication and access, and always open its door for authors worldwide.

© 2013-2017 by the Asia Press. All rights reserved.